华兰股份：拟设立全资子公司开展人工智能创新药研发解决方案及服务业务

Group 1 - The company plans to invest RMB 50 million to establish a wholly-owned subsidiary in Hainan Province for the development of artificial intelligence innovative drug research and development solutions and services [1] - In November 2024, the National Health Commission will release guidelines that promote the application of "artificial intelligence+" in drug development, aiming to advance innovation in the health industry [1]